The oncologist
Neoadjuvant TRK Inhibitors versus Chemotherapy in Advanced NTRK Fusion-Positive Sarcomas: A Real-World Evidence Analysis.
Fuyi Zhu, Haiyan Cheng, Yali Han, Shen Yang, Zhiyun Zhu, Qinghua Ren, Yan Su, Zhenni Wang, Hong Qin, Wei Yang, Shan Wang, Yijin Gao, Huanmin Wang
Published: 202510.1093/oncolo/oyaf401
Abstract
BACKGROUND: Despite the proven efficacy of TRK inhibitors in advanced NTRK fusion-positive sarcomas, chemotherapy remains the default first-line therapy in many developing countries. This real-world study directly compares outcomes of TRK inhibitors…
Preview only. Read the full abstract at the source